Skip to main content
PMC home page
Journal of Urban Health : Bulletin of the New York Academy of Medicine logoLink to Journal of Urban Health : Bulletin of the New York Academy of Medicine
. 2001 Jun;78(2):264–278. doi: 10.1093/jurban/78.2.264

Using a jail-based survey to monitor HIV and risk behaviors among seattle area injection drug users

Hanne Thiede 1,2,✉, Michael Romero 1, Keith Bordelon 3, Holly Hagan 1,2, Christopher S Murrill 1
PMCID: PMC3456353  PMID: 11419580

Abstract

Routine monitoring of human immunodeficiency virus (HIV) and risk behaviors among injection drug users (IDUs) is difficult outside drug treatment settings. We developed and implemented a survey of recently arrested IDUs to describe the prevalence of HIV, drug use, and sexual behaviors among them. A probability sampling survey was instituted in the King County Correctional Facility in Seattle, Washington, to sample recently arrested IDUs at the time of booking and in the jail health clinic between 1998 and 1999. Following HIV risk assessment and blood draw, additional information on drug use practices was gathered using a standardized questionnaire. Potential participants who were released from jail early could complete the study at a nearby research storefront office. Of the 4,344 persons intercepted at booking, 503 (12%) reported injection drug use, and 201 of the IDUs (40%) participated in the study. An additional 161 IDUs were enrolled in the study from the jail health clinic. Among the 348 unduplicated subjects, HIV prevalence was 2%; in the past 6 months, 69% reported two or more shooting partners, 72% used a cooker after someone else, 60% shared a syringe to divide up drugs, and 62% injected with used needles. Only 37% reported being hepatitis C seropositive, and 8% reported hepatitis B vaccination. It was feasible to conduct a jail-based survey of recently arrested IDUs that yielded useful information. The high prevalence of reported risky drug use practices warrants ongoing monitoring and illustrates the need for improving prevention programs for HIV and hepatitis B and C in this population, including expansion of hepatitis C screening and provision of hepatitis B vaccination at the jail health clinic.

Keywords: Correctional Facility, Hepatitis B and C Prevention, HIV, Injection Drug Users, Risk Behaviors

Full Text

The Full Text of this article is available as a PDF (151.6 KB).

References

  • 1.HIV/AIDS Surveillance Report. Atlanta, GA: Centers for Disease Control and Prevention; 1998. pp. 14–14. [Google Scholar]
  • 2.Des Jarlais DC, Marmor M, Friedmann P, et al. HIV incidence among injection drug users in New York City, 1992–1997: evidence for a declining epidemic. Am J Public Health. 2000;90:352–359. doi: 10.2105/AJPH.90.3.352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Des Jarlais DC, Perlis T, Friedman SR, et al. Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996. Am J Public Health. 1998;88:1801–1806. doi: 10.2105/AJPH.88.12.1801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Strathdee SA, Patrick DM, Currie SL, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS. 1997;8:F59–F65. doi: 10.1097/00002030-199708000-00001. [DOI] [PubMed] [Google Scholar]
  • 5.Dondero TJ, Pappaioanou M, Curran JW. Monitoring the levels and trends of HIV infection: the Public Health Service's HIV surveillance program. Public Health Rep. 1988;103:213–220. [PMC free article] [PubMed] [Google Scholar]
  • 6.Jones TS, Allen DM, Onorato IM, Peterson LR, Dondero TJ, Pappaioanou M. HIV seroprevalence surveys in drug treatment centers. Public Health Rep. 1990;105:125–130. [PMC free article] [PubMed] [Google Scholar]
  • 7.Pappaioanou M, Dondero TJ, Petersen LR, Onorato IM, Sanchez CD, Curran JW. The family of seroprevalence surveys: objectives, methods, and uses of sentinel surveillance for HIV in the United States. Public Health Rep. 1990;105:113–119. [PMC free article] [PubMed] [Google Scholar]
  • 8.Prevots DR, Allen DM, Lehman JS, Green TA, Petersen LR, Gwin M. Trends in human immunodeficiency virus seroprevalence among injection drug users entering drug treatment centers, United States, 1988–1993. Am J Epidemiol. 1996;143:733–742. doi: 10.1093/oxfordjournals.aje.a008807. [DOI] [PubMed] [Google Scholar]
  • 9.National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction Effective medical treatment of opiate addiction. JAMA. 1998;280:1936–1943. doi: 10.1001/jama.280.22.1936. [DOI] [PubMed] [Google Scholar]
  • 10.McCoy CB, Metsch LR, Chitwood DD, Shapshak P, Comerford ST. Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton and water. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:S25–S29. doi: 10.1097/00042560-199802001-00006. [DOI] [PubMed] [Google Scholar]
  • 11.Carpenter CL, Longshore D, Annon K, Annon JJ, Anglin MD. Prevention of HIV-1 among recent arrestees in Log Angeles County, California: serial cross-sectional study, 1991 to 1995. J Acquir. Immune Defic Syndr Hum Retrovirol. 1999;21:172–177. [PubMed] [Google Scholar]
  • 12.Hagan H, McGough JP, Thiede H, Weiss NS, Hopkins S, Alexander ER. Syringe exchange and risk of infection with hepatitis B and C ciruses. Am J Epidemiol. 1999;149:203–213. doi: 10.1093/oxfordjournals.aje.a009792. [DOI] [PubMed] [Google Scholar]
  • 13.Longshore D, Annon J, Anglin MD. Long-term trends in self-reported HIV risk behavior: injection drug users in Los Angeles, 1987 through 1995. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:64–72. doi: 10.1097/00042560-199805010-00010. [DOI] [PubMed] [Google Scholar]
  • 14.Koester S, Booth RE, Zhang Y. The prevalence of additional injection-related HIV risk behaviors among injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12:202–207. doi: 10.1097/00042560-199606010-00015. [DOI] [PubMed] [Google Scholar]
  • 15.National HIV Serosurveillance Summary, Results Through 1992. Atlanta, GA: Centers for Disease Control and Prevention; 1992. pp. 22–22. [Google Scholar]
  • 16.Vlahov D, Brewer F, Muñoz A, Hall D, Taylor E, Polk BF. Temporal trends of human immunodeficiency virus type 1 (HIV-1) infection among inmates entering a statewide prison system, 1985–1987. J Acquir Immune Defic Syndr. 1989;2:283–290. [PubMed] [Google Scholar]
  • 17.Rotily M, Vernay-Vaisse C, Boulière M, Galanier-Pujol A, Rousseau S, Obadia Y. HBV and HIV screening, and hepatitis B immunization programme in the prison of Marseille, France. Int J STD AIDS. 1997;12:753–759. doi: 10.1258/0956462971919228. [DOI] [PubMed] [Google Scholar]
  • 18.Rotily M, Galiner-Pujol A, Obadia Y, et al. HIV testing, HIV infection and associated risk factors among immates in south-eastern French prisons. AIDS. 1994;8:1341–1344. doi: 10.1097/00002030-199409000-00020. [DOI] [PubMed] [Google Scholar]
  • 19.Malliori M, Sypsa V, Psichogiou M, et al. A survey of bloodborne viruses and associated risk behaviours in Greek prisons. Addiction. 1998;93:243–251. doi: 10.1046/j.1360-0443.1998.9322438.x. [DOI] [PubMed] [Google Scholar]
  • 20.Bird AG, Gore SM, Cameron S, Ross AJ, Goldberg DJ. Anonymous HIV surveillance with risk factor elicitation at Scotland's largest prison, Barlinnie. AIDS. 1995;9:801–808. doi: 10.1097/00002030-199507000-00019. [DOI] [PubMed] [Google Scholar]
  • 21.Edwards A, Curtis S, Sherrard J. Survey of risk behavior and HIV prevalence in an English prison. Int J STD AIDS. 1999;10:464–466. doi: 10.1258/0956462991914474. [DOI] [PubMed] [Google Scholar]
  • 22.Vlahov D, Brewer TF, Castro KG, et al. Prevalence of antibody to HIV-1 among entrants to US correctional facilities. JAMA. 1991;265:1129–1132. doi: 10.1001/jama.265.9.1129. [DOI] [PubMed] [Google Scholar]
  • 23.Centers for Disease Control and Prevention HIV prevention in the US correctional system, 1991. MMWR Morb Mortal Wkly Rep. 1992;42:389–397. [PubMed] [Google Scholar]
  • 24.Polonsky S, Kerr S, Harris B, Gaiter J, Fichtner RR, Kennedy MG. HIV prevention in prisons and jails: obstacles and opportunities. Public Health Rep. 1994;109:615–625. [PMC free article] [PubMed] [Google Scholar]
  • 25.Mahon N. New York inmates' HIV risk behaviors: the implications for prevention policy and programs. Am J Public Health. 1996;86:1211–1215. doi: 10.2105/AJPH.86.9.1211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Dean-Gaitor HD, Fleming PL. Epidemiology of AIDS in incarcerated persons in the United States, 1994–1996. AIDS. 1999;13:2429–2435. doi: 10.1097/00002030-199912030-00015. [DOI] [PubMed] [Google Scholar]
  • 27.Reindollar RW. Hepatitis C and the correctional population. Am J Med. 1999;107:100S–103S. doi: 10.1016/S0002-9343(99)00394-0. [DOI] [PubMed] [Google Scholar]
  • 28.Hammett TM, Gaitor JL, Crawford C. Reaching seriously at-risk populations: health interventions in criminal justice setting. Health Educ Behav. 1998;25:99–120. doi: 10.1177/109019819802500108. [DOI] [PubMed] [Google Scholar]
  • 29.Centers for Disease Control and Prevention Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep. 1998;47(RR 19):1–39. [PubMed] [Google Scholar]

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES